Stock 002603 SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
18.16 CNY +1.28% Intraday chart for Shijiazhuang Yiling Pharmaceutical Co., Ltd. -2.00% -21.28%
May. 23 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend Per 10 Shares for 2023 CI
Apr. 26 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend Per 10 Shares for 2023
CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug
MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%
MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules
MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug
MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules
MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023
CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022
CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China
MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022
CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules
MT
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine
MT
Yiling Pharma’s Traditional Chinese Medicine Added to Government's Recommended Drugs For COVID-19
MT
Shijiazhuang Yiling Pharma Secures Regulatory Nod For Traditional Chinese Medicine Trial
MT
Yiling Pharma Denies Claims That COVID-19 Drug May Cause Liver Injury
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002603 Stock
  4. News Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  5. Highlights